Comparative Pharmacology
Head-to-head clinical analysis: BENZONATATE versus TUZISTRA XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENZONATATE versus TUZISTRA XR.
BENZONATATE vs TUZISTRA XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Benzonatate is a local anesthetic structurally related to tetracaine. It suppresses cough by anesthetizing stretch receptors in the respiratory tract, reducing the cough reflex.
Tuzistra XR is a combination of codeine (an opioid agonist) and promethazine (a phenothiazine derivative with antihistaminic, sedative, and anticholinergic effects). Codeine binds to mu-opioid receptors in the CNS, inhibiting cough reflex. Promethazine acts as a histamine H1 receptor antagonist and may have additional central anticholinergic and sedative effects.
100 mg to 200 mg orally three times daily as needed for cough.
Initial: 25 mg orally twice daily; may increase to 50 mg twice daily after 1 week based on tolerability; maximum 50 mg twice daily.
None Documented
None Documented
Terminal elimination half-life is approximately 3–8 hours in adults; prolonged in hepatic impairment.
Terminal elimination half-life is 7 hours for the parent drug; clinically, this supports twice-daily dosing for sustained symptom relief.
Primarily renal excretion of metabolites; unchanged benzonatate is negligible. Fecal elimination accounts for <5%. Biliary excretion is minimal.
Primarily hepatic metabolism via glucuronidation; approximately 20% of the dose is excreted unchanged in urine, and 80% is eliminated as metabolites in feces via biliary excretion.
Category A/B
Category C
Antitussive
Antitussive/decongestant combination